Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Notes Payables (2022)

RedHill Biopharma has reported Notes Payables over the past 1 years, most recently at $115.2 million for Q4 2022.

  • Quarterly Notes Payables changed N/A to $115.2 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $115.2 million through Dec 2022, changed N/A year-over-year, with the annual reading at $115.2 million for FY2022, N/A changed from the prior year.
  • Notes Payables was $115.2 million for Q4 2022 at RedHill Biopharma.
  • Over five years, Notes Payables peaked at $115.2 million in Q4 2022 and troughed at $115.2 million in Q4 2022.